Detailed Information on Publication Record
2018
Development of selective casein kinase 1 delta/epsilon inhibitors for cancer
GREGOROVÁ, Michaela, Pavlína JANOVSKÁ, Václav NĚMEC, Michaela SCHOLASTEROVÁ, Jan VERNER et. al.Basic information
Original name
Development of selective casein kinase 1 delta/epsilon inhibitors for cancer
Authors
GREGOROVÁ, Michaela (203 Czech Republic, belonging to the institution), Pavlína JANOVSKÁ (203 Czech Republic, belonging to the institution), Václav NĚMEC (203 Czech Republic, belonging to the institution), Michaela SCHOLASTEROVÁ (203 Czech Republic, belonging to the institution), Jan VERNER (203 Czech Republic, belonging to the institution), Lucie POPPOVÁ (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Kamil PARUCH (203 Czech Republic, belonging to the institution) and Vítězslav BRYJA (203 Czech Republic, guarantor, belonging to the institution)
Edition
HemaSpehere, 2018
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
10601 Cell biology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14310/18:00105988
Organization unit
Faculty of Science
ISSN
Keywords in English
Therapy - Wnt - Inhibitor
Tags
International impact
Změněno: 31/1/2019 07:50, Mgr. Zuzana Jašková, Ph.D.
Abstract
V originále
Casein kinase 1 (CK1) is a key component of both canonical and non-canonical Wnt pathways, which were shown to drive chronic lymphocytic leukemia (CLL) by several mechanisms (Wang et al., 2014, Kaucka et al., 2013). Also other types of cancer, such as breast, prostate cancer or others were previously shown to depend on Wnt/CK1 activity and the pathway inhibition was suggested as a potential form of therapy. In recent study, we showed that CK1 inhibition can block processes involved in CLL progression in vitro as well as in vivo in the Eµ-TCL1 mouse model of CLL (Janovska et al., 2018). Importantly, CK1 inhibition showed synergistic effects with ibrutinib treatment in blocking chemotaxis of CLL cells, a process important for CLL pathogenesis and showed to be beneficial also in vivo.
Links
| MUNI/A/0968/2017, interní kód MU |
|